Very late-onset membranous nephropathy secondary to alemtuzumab in a patient with multiple sclerosis
Nefropatía membranosa muy tardía secundaria a alemtuzumab en paciente con esclerosis múltiple
Área salud
Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab
Late-onset neutropaenia is defined as an absolute neutrophil count of 4 weeks after the last dose of rituximab, in the absence of other identifiable causes. Late-onset neutropaenia is a rare adverse reaction to rituximab (observed […]
Área salud
Monitoring response to disease-modifying treatment in multiple sclerosis
Background Standard criteria for defining suboptimal response to disease-modifying treatment (DMT) in patients with multiple sclerosis (MS) are lacking. Decision-making on how and when DMTs should be switched is challenging. The objective of the study […]
Área salud
Gadolinium-enhanced brain lesions in multiple sclerosis relapse
Objective To study the clinico-radiological paradox in multiple sclerosis (MS) relapse by analyzing the number and location of gadolinium-enhanced (Gd+) lesions on brain MRI before methylprednisolone (MP) treatment. Methods We analyzed brain MRI from 90 […]